Join
Live feed
·
INSIDERFilingvia Quantisnow
Aclaris Therapeutics Inc. logo

INTERIM CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 3,559 shares, increasing direct ownership by 0.41% to 1,460,718 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ACRS· Aclaris Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRS (Aclaris Therapeutics Inc.) and more on Quantisnow.